First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects

Cancer Biol Med. 2023 Dec 26;21(2):117-124. doi: 10.20892/j.issn.2095-3941.2023.0401.

Authors

Jingyi Wang^{1

2}, Lin Wu¹

Affiliations

¹ The Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
² Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.

PMID: 38148394
PMCID: PMC10884539
DOI: 10.20892/j.issn.2095-3941.2023.0401

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Immunotherapy
Lung Neoplasms* / drug therapy

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized

Grants and funding